International review of neurobiologyHumansMyasthenia GravisAdrenal Cortex HormonesOutcome AssessmentHealth Care
Measuring treatment related side effect burden in myasthenia gravis.
Michael K Hehir, James F Howard
Published: 202510.1016/bs.irn.2025.04.019
Abstract
Treatment options for patients with myasthenia gravis (MG) are rapidly increasing. Seven new MG therapies across 2 novel classes have been approved by the FDA to treat MG; a robust treatment pipeline spans at least 7 novel therapeutic classes. Intern…
Preview only. Read the full abstract at the source